Because T cell-derived cytokines may affect the functioning of eosinophils, we have investigated the capacity of human eosinophils to respond to IL-2. IL-2 was a potent chemoattractant with EDI0 of 10-12 M with eosinophils from all normal and eosinophilic donors tested. The monoclonal antibodies anti-Tac and TU27 against p55 (Tac/CD25) and p75 receptor subunits, respectively, each inhibited IL-2-dependent eosinophil migration. The molar potency of IL-2 and the inhibitory activity of each of the above antibodies suggest that high affinity heterodimeric IL-2 receptor complexes mediated the migration responses of eosinophils to IL-2. Binding of monoclonal antibody against p75 was not detectable by flow cytometry, and high affinity binding sites for "25I-IL-2 were below the limits ofquantitation on eosinophils from individuals with eosinophilia. Expression of p55 (Tac/CD25) by eosinophils, without requirement for in vitro activation, was demonstrable by flow cytometry, radioimmunoprecipitation, and Northern blotting for mRNA. Surface expression of p55 on eosinophils from normal or eosinophilic individuals increased during culture for 24-48 h with a biologic activity purified from stimulated U937 cells and to a lesser extent with granulocyte-macrophage CSF or lymphocyte chemoattractant factor but not with nine other cytokines. These studies indicate that blood eosinophils respond to IL-2 and identify one mechanism whereby activation of T lymphocytes may influence the function of eosinophils. (J. Clin.
Introduction
Development of high affinity receptors for IL-2 is a crucial process in proliferative responses of lymphoid cells. The current model of the high affinity IL-2 receptor (IL-2R) complex includes, at a minimum, two noncovalently associated subunits, p55 and p75 (1) . Individually, p55 and p75 bind IL-2 with low or intermediate affinity, respectively (2) (3) (4) . The p55 subunit, designated CD25, is recognized by antibodies such as anti-Tac (5) . In lymphocytes, p55 is transcriptionally regulated; induction of this peptide correlates with acquisition of high affinity binding sites and biologic responsiveness to IL-2 during lymphocyte activation (1) .
In addition to the studies of the IL-2R of lymphocytes, IL-2R have been identified by the binding of CD25 MAb on selected myelomonocytic cell types. Neither promyelocytes nor more mature neutrophils expressed CD25, but CD25 expression was found on acute myeloid leukemia (AML)1 blast cells and increased during culture with PMA, IFN--y, the cytokine adult T cell leukemia-derived factor (ADF), or an impure source of granulocyte-macrophage colony-stimulating factor (GM-CSF) (6, 7) . Chronic myeloid leukemia (CML) blast cells expressed CD25 only after cell culture, whereas normal bone marrow cells similarly cultured did not express CD25 (8) . Basophils purified from CML or normal donors expressed CD25, as did mast cells in tissue sections (9, 10) . In the instances in which radioligand binding studies were performed, these various myeloid cells had low to intermediate-affinity binding sites for IL-2 (6-10). Monocytes, on the other hand, constitutively express p75; and p55/CD25 is inducible along with highaffinity IL-2R during in vitro activation or diseases associated with monocyte activation (11) (12) (13) (14) . CD25 expression could be detected on the promyelocytic leukemia cell line HL60 only after treatment with IFN-T, which induced monocytic differentiation (1 1). These studies have delineated distinct patterns of IL-2R subunit expression and offer the possibility that IL-2 activates diverse functions on a variety of cell types.
Eosinophils are a distinctive lineage ofgranulocytes. Eosinophils normally constitute less than 3% of circulating leukocytes and are distributed predominantly in submucosal areas of the respiratory and gastrointestinal tracts. In diseases associated with eosinophilia, various T lymphocyte products are responsible for accelerated production and tissue localization ofeosinophils (15) . Because IL-2 is a major cytokine product of activated T lymphocytes, we have evaluated the expression of IL-2R on human eosinophils. Eosinophils express functional IL-2R, and IL-2 can stimulate eosinophils, as evidenced by its capacity to induce receptor-dependent eosinophil migration.
Methods
Blood donors and eosinophil isolation. Eosinophils were obtained from two donors with the idiopathic hypereosinophilic syndrome (HES) (16) , one of whom was being treated with intermittent chlorambucil and hydroxyurea and the other required no therapy. Granulocytes were isolated by dextran sedimentation, centrifugation through Ficoll-Paque (Pharmacia, Piscataway, NJ), and hypotonic lysis of erythrocytes.
1. Abbreviations used in this paper: ADF, adult T cell leukemia-derived factor, AML, acute myeloid leukemia; CML, chronic myeloid leukemia; ECEF, eosinophil cytotoxicity-enhancing factor; HES, idiopathic hypereosinophilic syndrome; IL-2R, IL-2 receptor(s); LCF, lympho-These HES granulocyte preparations contained 74±13% eosinophils (mean±SD, 26 isolations) with neutrophils as the only contaminating cells. Eosinophils (purity 70%) were isolated by the Percoll (Pharmacia) gradient technique described below from a patient with filariasis with 12% blood eosinophilia on no therapy.
From seven normal donors, on no medications and preselected for 2-6% peripheral blood eosinophilia, eosinophils were isolated on Percoll gradients as described (17) . Similar to recently published procedures for depletion ofCD 16+ neutrophils (18) , eosinophils were further purified by sequential incubation at 40C with the CD16 MAb 3G8 (purified from supernatant of the hybridoma [ 19] , a gift of Dr. Martin Sanders, Upjohn Co., Kalamazoo, MI) at 2 ,ug per 107 granulocytes and goat anti-mouse IgG magnetic beads (Advanced Magnetics, Cambridge, MA) at 20 beads per antibody-coated granulocyte. The final preparations contained 70±23% eosinophils (mean±SD, 6 isolations) with neutrophils as the only contaminating cells. In selected experiments, immunodepletion of CD16' neutrophils was repeated to yield 100% pure eosinophils.
Percentage of eosinophils was determined after fast green staining ofcytocentrifuge preparations. In selected experiments, monocyte contamination was undetectable (less than one per 500 granulocytes) by a-naphthyl esterase staining (Sigma Chemical Co., St. Louis, MO) of purified eosinophils. Binding of the monocyte MAb Leu M3 (CD14; Becton-Dickinson, Mountain View, CA) or T lymphocyte MAb Leu 1 (CD5, Becton-Dickinson) was undetectable in comparison with IgG subclass controls by flow cytometry on purified eosinophils. Viability by trypan blue or propidium iodide exclusion was greater than 98%.
Culture ofeosinophils with cytokines. Purified eosinophils were cultured in plastic tissue culture flasks (model 3013; Falcon, Oxnard, CA) at 0.5-1 X 106/ml in complete medium: RPMI 1640 (JRH Biosciences, Lenexa, KS) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 ,ug/ml streptomycin, and 10% FCS (Gibco, Grand Island, NY). After culture, monocytes and T lymphocytes were undetectable as assessed above.
Three sources of recombinant human IL-2 were found comparable in effects on eosinophils: (Genzyme, Boston, MA) 2.5 X 106 U/mg, (R&D Systems, Minneapolis, MN) 3 X 106 U/mg, or (Peprotech, Rocky Hill, NJ) 5 X 106 U/mg. Proliferation of the IL-2-dependent murine cell line CTLL by colorimetric assay (20) confirmed the activities reported by the manufacturers for the IL-2 preparations. Other recombinant human cytokine sources were as follows: affinity-purified ADF (21) (gift of Dr. Junji Yodoi, Virus Research Institute, Kyoto, Japan), GM-CSF (Genzyme) 2.5 X I05 CFU/Mg; IFN-,y (Genzyme) 2.5 x I0' U/mg; IL-I ,B (Genzyme) 2 X 108 U/mg; IL-3 (Genzyme) 5 X I07 U/mg; IL-4 (Genzyme) 1 X 108 U/mg; IL-5 (Amgen, Thousand Oaks, CA) 1 x 106 U/mg; IL-6 (Peprotech) EDo with B9 cells 0.2 ng/ml; and lymphocyte chemoattractant factor (LCF)-containing COS cell supernatant (gift of Dr. David Center, Boston University School of Medicine, Boston, MA), ED5o 1 :10,000 in eosinophil chemotaxis (the ED5o of purified LCF is 0.1 ng/ml) (17) .
A partially purified supernatant containing eosinophil cytotoxicityenhancing factor (ECEF) and ADF was generated from the U937 monocytic cell line by stimulation with 100 ng/ml PMA and S Mg/ml LPS (butanol extract ofEscherichia coli 01 27:B8; Sigma Chemical Co.) followed by ammonium sulfate fractionation and phenyl-Sepharose and DEAE ZetaChrom-250 chromatography as detailed previously (22) . The material was reconstituted in complete medium at the original volume of the U937 supernatant and used at specified dilutions thereof. Endotoxin activity by Limulus assay (23) was 12 ng/ml for the purified undiluted material. ECEF activity in enhancing eosinophil killing of Schistosoma mansoni schistosomula was assayed as previously described (22) . Two separate preparations were comparable in both ECEF activity and enhancement of eosinophil CD25. Homogenously pure ECEF was isolated from the partially purified supernatant by preparative SDS-PAGE and electroelution of the gel slice of M, 10 ,000 as detailed previously (22 uct ofthe "bindability" and the difference between radioactivity added and that specifically bound. PHA lymphoblasts derived from PBMC cultured at 10'/ml for 3 d with 2 jtg/ml PHA (Difco, Detroit, MI) were used as a positive control expressing IL-2R. Assessment of eosinophil migration. Eosinophil migration assays employed our previously described techniques by which eosinophils migrating at several distances into thick nitrocellulose membranes were selectively stained with the fluorescent dye aniline blue and enumerated using fluorescence microscopy and an image analyzer (29) . Eosinophils (1-2 X I0O per well) were suspended in HBSS containing I mg/ml ovalbumin (Sigma Chemical Co.) and added to the upper wells of microchemotaxis chambers (Neuroprobe, Cabin John, MD), which were separated by a 5-Mgm pore nitrocellulose filter from the chemoattractant in the lower wells. After 60 min at 370C, the filters were stained with aniline blue. Four 25X fields per well were quantified by counting the fluorescent images of eosinophils at 10-Mm intervals beginning 10 Mm from the upper surface (in general three to four levels within the filter were counted), as described in detail (29) , except that the microscope was a Leitz Laborlux S with a 50 Wlamp. Results are expressed as migration index, which is calculated as the sum of the products of cell numbers migrated at each level times the distance for each level counted. Known positive stimuli for eosinophil migration included platelet-activating factor, L-a-phosphatidylcholine f3-acetyl--y-O-hexadecyl (PAF; Sigma Chemical Co.), HPLC-purified recombinant human C5a (gift of Dr. Norma Gerard, Beth Israel Hospital, Boston, MA), and CD4-affinity-purified recombinant LCF (17, 30, 31 (Fig. 1) , equivalent to 0.05 U/ml based on IL-2-dependent proliferation assay, and the same EDIc was found with recombinant IL-2 from three manufacturers. On a molar basis in comparison with the recognized eosinophil chemoattractants C5a and platelet-activating factor (PAF), IL-2 was -1000-fold more potent (Fig. 1) . Eosinophils from all donors tested, six normal and two eosinophilic donors, responded to IL-2 (Table I ). In comparisons of eosinophil migration in response to the optimum concentrations for each stimulus, IL-2 at 10-10 M was comparably active to LCF (17) at 10-10 M, C5a at I0-' M, and PAF at 10-6 M. In order to determine whether eosinophil migration responses to IL-2 required a chemotactic gradient, we performed checkerboard analyses (33) ( Table II) . The predominant effect of IL-2 on eosinophil migration was chemokinesis (dose-dependent stimulation of migration independent of a concentration gradient). Thus, IL-2 can elicit functional responses in eosinophils, and the responses occur with low concentrations ofIL-2 indicative ofthe involvement of high affinity IL-2R.
We performed antibody blocking experiments to test whether both p75 and p55 Tac subunits of the high affinity IL-2R complex participate in IL-2-induced eosinophil migration. MAb to either p55 (anti-Tac) or p75 (TU27) inhibited the eosinophil chemoattractant response to IL-2 (Fig. 2) . IgG subclass controls were not inhibitory. In a total of five experiments, inhibition of IL-2-elicited eosinophil chemotaxis by anti-Tac (25 gg/ml) was 91±20%, and inhibition by TU27 (25 ,gg/ml or 1:400 dilution of ascites) was 82±28%. blasts (mean 66% CD25' by flow cytometry) revealed a curvilinear Scatchard plot which could be fitted by two affinities of binding sites: 800±300 high affinity sites per cell with an apparent Kd of 3±2 X 10-" M, and 11,000±2,000 low affinity sites per cell with an apparent Kd of 6±1 X 10-9 M (n = 3). Thus, minimal numbers of high affinity IL-2R could be detected on eosinophils of one of three donors. Eosinophil IL-2R expression analyzed by flow cytometry. Expression ofp55 was measured by flow cytometry with CD25 MAb. Eosinophils from all donors expressed low levels of CD25: mean (range) in percentage CD25' were 28% (9-54%) for HES eosinophils (n = 11 from 2 donors), 38% for eosinophils from a filariasis patient, and 9% (4-17%) for eosinophils from normal donors (n = 3); mean (range) in AMFI were 8.9 (4.7-15.5) for HES eosinophils, 4.3 for eosinophils from a filariasis patient, and 2.4 (1.8-2.8) for normal eosinophils. In contrast, expression of p75 measured by flow cytometry with TU27 MAb was not detectable on eosinophils from normal or eosinophilic donors (n = 8).
Identity of the surface antigen which binds CD25 MAb as p55 Tac. To ascertain that the eosinophil surface antigen recognized by CD25 MAb was the p55 Tac subunit of IL-2R, we performed radioimmunoprecipitation. HES eosinophils, purified to 100% with two cycles of immunodepletion of CD16+ neutrophils, were cultured with a partially purified U937 supernatant that enhances CD25 expression (see below). By flow cytometry, eosinophils demonstrated a unimodal pattern of 2A3 CD25 MAb staining (Fig. 3 A) , and eosinophils were 56% CD25+. On analysis of cell surface radioiodinated eosinophils (Fig. 3 B) , immunoprecipitation with subclass IgG control mRNA for p55 Tac in eosinophils. To investigate mechanisms of IL-2R expression by eosinophils, we examined mRNA by Northern blot analysis. mRNA for p55 Tac was present in freshly isolated HES eosinophils (Fig. 4, lane 1) .
PBMC isolated from the same blood specimen contained much less mRNA for p55 IL-2R (lane 2), similar to findings with normal PBMC in which p55 mRNA was minimal without in vitro stimulation (1) . The lesser mRNA expression in PBMC also established that the finding of p55 mRNA in purified eosinophils was not attributable to mononuclear cell contamination (500-cell differential counts of the purified eosinophils contained no mononuclear cells). The two sizes ofp55 mRNA in eosinophils were at the same positions as the 3. (Fig. 5) . Before cell culture, eosinophils varied in CD25 expression as noted above. The cytokines evaluated were the colony-stimulating factors active on eosinophils (GM-CSF, IL-3, and IL-5), IFN-y, LCF, and a partially purified U937 supernatant which contained ECEF and ADF (22) . The only material that consistently enhanced CD25 on HES eosinophils during 24-48-h culture was the U937-derived material.
Comparison of CD25 expression on eosinophils cultured in medium versus U937-derived factor was significant whether analyzed as percentage CD25' (P < 0.001, the increase in percentage CD25' was 22±3, n = 13) or as MFH (P < 0.005, the increase in MFI was 5.1 ± 1.0). The capability for enhanced p55 IL-2R expression by normal eosinophils was evident in experiments with the U937-derived activity: after culture eosinophils from three normal donors were 63, 38, and 14% CD25'. GM-CSF and LCF each increased eosinophil CD25 expression in some but not all experiments, and overall the increases were statistically significant. IFN-'y significantly depressed CD25 expression in comparison to the effects of culture in medium alone, but the magnitude ofthe effect was small. IL-3 increased CD25 in individual experiments, sometimes dramatically, but overall the effects were not statistically significant. No trends were evident in the effects ofIL-5. Other cytokines that did not influence eosinophil CD25 expression included IL-1I, (10- Statistical differences from medium treated were U937 treated at P < 0.001, IFN treated or GM-CSF treated at P < 0.01, LCF treated at P < 0.05; data from eosinophilic and normal donors were analyzed together since changes were in the same direction for each group. (Fig. 6) . The enhancement by the U937-derived factor was detectable at 24 h and increased further by 48 h. Flow cytometry histograms are shown in A to illustrate the change in eosinophil CD25 during culture with U937-derived factor. IFN-,y persistently depressed CD25. The magnitude of CD25 expression during culture with GM-CSF or medium alone was similar to that on freshly isolated eosinophils. These experiments were not extended beyond 48 Because p55/CD25 expression was greater on eosinophils from eosinophilic diseases compared with normal eosinophils, we evaluated stimuli that might modulate eosinophil CD25 expression including cytokines known to have activities for eosinophils. GM-CSF and IL-3, colony-stimulating factors with similar activities for eosinophils, did not consistently upregulate eosinophil CD25, although the increases in CD25 with GM-CSF attained statistical significance. The results with IL-3 are of interest in relationship to the report that IL-3 enhanced p55 IL-2R on murine hemopoietic cell lines (40) . LCF, a chemoattractant for CD4' leukocytes including eosinophils (17) , upregulated CD25 expression of CD4' lymphocytes (41) and significantly but minimally increased eosinophil CD25 under the conditions examined. A number of cytokines that failed to enhance CD25 on eosinophils do so on other cell types: IFN-'y enhanced monocyte pSS/CD25; IL-2 and IL-S enhanced lymphocyte pSS/CD25 (1, 11, 12, 42, 43) . The dichotomy between monocytes and eosinophils with regard to the effect ofIFN-y is ofinterest, as with both eosinophils and monocytes IFN-'y stimulates cytotoxicity (44) and induces HLA-DR (Rand, T. H., and P. F. Weller, unpublished results). The effects ofpharmacologic agents suggest that intracellular events responsible for enhancement of p55 IL-2R may be quite different in eosinophils from those in lymphocytes: PMA, which activates protein kinase C, A23187, which increases cytoplasmic calcium, and forskolin, which increases cAMP are activators oftranscription of mRNA for p55 in lymphocytes (1, 34, 35) but did not influence p55/CD25 expression of eosinophils.
The only stimulus that consistently enhanced pS5/CD25 expression was an activity partially purified from stimulated U937 cells. Endotoxin was not responsible for the U937 supernatant activity: LPS did not enhance eosinophil CD25 expression either by itself or after addition to the partially purified U937 supernatant. The U937-derived material was purified based on its ECEF activity, defined by eosinophil killing of target parasites. When the chromatographically purified material is subjected to its final purification step (elution from SDSpolyacrylamide gels) there is considerable loss ofECEF activity (22) ; it is conceivable that loss ofCD25-enhancing activity may have occurred as well. Against this interpretation, however, was the finding that an antibody that neutralizes ECEF did not decrease the CD25-enhancing activity ofthe U937-derived material. We also considered the possibility that a molecularly related factor ADF was present in the partially purified U937 supernatant. ADF enhanced pSS/CD25 expression on a variety oflymphoid cells and AML cells (7, 21) . The 13,000-M, ADF is similar physicochemically to the 10,000-M, ECEF, and they share NH2-terminal amino acid sequence homology with thioredoxin (21, 22) . However, neither pure ECEF nor ADF upregulated eosinophil CD25; hence, the biologic activity from U937 cells remains unidentified.
There are a number of immunopathologic correlations between IL-2 and eosinophils, but the immunologic roles served by IL-2R on eosinophils are not certain. Elevated serum levels of soluble IL-2R have been noted in patients with HES, although these soluble IL-2R may have been lymphocyte derived (45) . In view of the activity of IL-2 as a chemoattractant, IL-2 could contribute to the recruitment of eosinophils to sites of lymphocyte activation. Concomitant infiltration of eosinophils and activated IL-2R-bearing lymphocytes have been noted, for instance, in the respiratory tract in chronic asthma (46) . IL-2 administered in the bladder, peritoneum, and pleural space has been followed by local eosinophilia, but repeated high doses of IL-2 were used over days to weeks, which also resulted in blood eosinophilia (47) (48) (49) . Systemic administration of IL-2 frequently results in eosinophilia, and the blood eosinophils have an activated phenotype (50) , findings that could be secondary to IL-5 produced by IL-2-activated lymphocytes (51 
